Switching of Sildenafil to Riociguat in CTEPH Patients
Status:
RECRUITING
Trial end date:
2027-01-22
Target enrollment:
Participant gender:
Summary
This study was designed to investigate the safety and efficacy of replacing phosphodiesterase 5 inhibitors (PDE5i) with riociguat in patients with Chronic thromboembolic pulmonary hypertension (CTEPH) who have undergone pulmonary angioplasty (BPA) and remains symptomatic despite treatments with PDE5i.